| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910789244103321 |
|
|
Titolo |
Clinical and statistical considerations in personalized medicine / / edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Boca Raton : , : CRC Press, , [2014] |
|
©2014 |
|
|
|
|
|
|
|
|
|
ISBN |
|
0-429-16933-7 |
1-4665-9387-3 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (368 p.) |
|
|
|
|
|
|
Collana |
|
Chapman and Hall/CRC Biostatistics Series |
|
|
|
|
|
|
Classificazione |
|
MAT029000MED045000MED071000 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
|
|
Soggetti |
|
Pharmacogenetics - Mathematical models |
Pharmacogenetics - Statistical methods |
Pharmacogenomics - Mathematical models |
Pharmacogenomics - Statistical methods |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
Front Cover; Contents; Preface; Editors; Contributors; Chapter 1: Biomarkers for Drug Development: The Time Is Now!; Chapter 2: RNAi Screens: Triumphs and Tribulations; Chapter 3: Current Advances in Epigenetics; Chapter 4: Biomarkers and Precision Medicine: The Case of Rare Diseases; Chapter 5: Biomarker-Informed Adaptive Design; Chapter 6: Fitting the Dose: Adaptive Staggered Dose Design; Chapter 7: Evidence-Based Adaptive Statistical Decision and Design Strategies for; Chapter 8: Biomarker Identification in Clinical Trials; Chapter 9: Multiplicity in Pharmacogenomics |
Chapter 10: Patient-Reported Outcomes in Personalized MedicineChapter 11: Regulatory Issues in Use of Biomarkers in Drug Development; Back Cover |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Personalized medicine has the potential to change the way we think about, identify, and manage health problems. In the pharmaceutical industry, it is already having an exciting impact on both clinical |
|
|
|
|
|
|
|
|
|
|
research and patient care. This impact will continue to grow as our understanding and technologies improve. With contributions from well-known industry leaders in clinical development, this book covers the practical aspects of personalized medicine, focusing on issues that have direct application in the industry. Topics include designs for targeted therapy, adaptive designs, evidence-based adaptive statistical decisions, and design strategies for maximizing the efficiency of clinical oncology-- |
|
|
|
|
|
| |